Alembic Pharmaceuticals on Tuesday (17 March) said it received an establishment inspection report (EIR) from the US drug regulator for its facility at Karakhadi in Gujarat.
"This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our API (Active Pharmaceutical Ingredient) facility at Karakhadi during the period from 13th January, 2020 to 17th January, 2020," the company said in a statement.Alembic Pharmaceuticals is engaged developing formulations and active pharmaceutical ingredients (API).
On a consolidated basis, the pharmaceutical company's net profit rose 37.9% to Rs 234.19 crore on a 18.8% rise in the net sales to Rs 1209.13 crore in Q3 December 2019 over Q3 December 2018.
The scrip was currently down 0.25% at Rs 529.75. It has fallen 19.64% in nine sessions from its recent closing high of Rs 659.25 recorded on 3 March 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
